Compared to mice treated with PBS, gefitinib or CMV-scrR, mice treated with the CMV-siRE circuit showed (1) a markedly increased overall survival rate (Fig. 3b); (2) an almost completely diminished lung tumor burden (Fig. 3c, d and Supplementary information, Figs. S18, S19); (3) largely reversed lung tumor histology (Fig. 3e); (4) a significant decrease in EGFR protein and mRNA to nearly normal levels in lung tumors (Fig. 3f, h, i); and (5) a significantly decreased tumor cell proliferation rate (Fig. 3g). Here, EGFR is linked to neoplasm.